Toremifene (brand name: Fareston) is a relatively new anti-estrogen SERM with properties and side effects similar to tamoxifen's. Unlike tamoxifen, toremifene does not seem to increase the risk of endometrial cancer. Based on research available to date, the Food and Drug Administration (FDA) has restricted the use of toremifene to post-menopausal women with metastatic breast cancer.